Skip to main content
Premium Trial:

Request an Annual Quote

Atantares Closes Early Financing Rounds, Raising RMB 100M

NEW YORK – China's Atantares, a biology-focused semiconductor chip maker, has closed two pre-Series A financing rounds, for a total of RMB 100 million ($13.9 million).

Asia Green Fund led the first round, joined by Fosun Health Capital and existing investors Frees Fund, Qiming Venture Partners, Next Capital, and NeuX Capital.

Alibaba Health exclusively invested in the other round.

In a statement, the firm said the funds will be used for R&D and operations and to expand capacity.

"We expect Atantares to continue to overcome difficulties and become a global leader in the strategic competition for underlying technologies like long-chain DNA synthesis and gene storage," Asia Green Fund Managing Director Kuan Huang said in a statement.

Founded in 2021, Atantares seeks to develop chips for use in biotechnology. The firm has applied its chips toward high-throughput DNA synthesis.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.